Shares of other companies:
April 24, 2024 Google’s Third Cookie Phaseout Delay Amid Regulatory Hurdles
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
April 18, 2024 EU Moves Toward Single Capital Market Union
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
Amazon Web Services Expands Bedrock GenAI Service
April 23, 2024
Why Microsoft Stands Out As A Pre-Earnings Buy
April 23, 2024
Wall Street Lunch: Big Tech Bearishness?
April 22, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
EXEL Stock News and Mentions of Exelixis, Inc. Stocktwits
Updated: April 25, 2024 (13:15)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Exelixis Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Exelixis, Inc. (EXEL).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Exelixis stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Exelixis, Inc. (EXEL)
April 23, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is SPDR S&P Biotech ETF ( XBI ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
April 23, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Exelixis Getting Closer To Key Technical Benchmark
Exelixis ( EXEL ) had its Relative Strength ( RS ) Rating upgraded from 69 to 75 Tuesday - a welcome improvement, but still short of the 80 or better score you look for.
In Article Trend: Bullish
April 17, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Exelixis Getting Closer To Key Technical Benchmark
Exelixis ( EXEL ) had its Relative Strength ( RS ) Rating upgraded from 68 to 71 Wednesday - a welcome improvement, but still below the 80 or better score you prefer to see.
In Article Trend: Bullish
April 11, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Exelixis Sees IBD RS Rating Improve To 71
On Thursday, Exelixis ( EXEL ) received an upgrade to its Relative Strength ( RS ) Rating, from 65 to 71. X IBD's unique rating tracks share price action with a 1 ( worst ) to 99 ( best ) score. The rating shows how a stock's price performance over the trailing 52 weeks compares to all the ...
In Article Trend: Bullish
April 9, 2024 (15:40) / "Zacks Commentary" (by Zacks Equity Research)
EXEL or REGN: Which Is the Better Value Stock Right Now?
EXEL vs. REGN: Which Stock Is the Better Value Option?
In Article Trend: Bullish
March 23, 2024 (09:06) / "Motley Fool" (by Sean Williams)
4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.
In Article Trend: Somewhat-Bullish
March 13, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Immunovant, Inc. ( IMVT ) Down 14.7% Since Last Earnings Report?
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 11, 2024 (14:36) / "Zacks Commentary" (by Zacks Equity Research)
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys are part of the Zacks top Analyst Blog.
In Article Trend: Somewhat-Bullish
March 8, 2024 (13:15) / "Motley Fool" (by Prosper Junior Bakiny)
2 Biotech Stocks to Buy Hand Over Fist in March
These stocks are worth buying in most months of the year.
In Article Trend: Somewhat-Bullish
March 8, 2024 (12:31) / "Zacks Commentary" (by Nalak Das)
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.
In Article Trend: Somewhat-Bullish
March 7, 2024 (16:31) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Exelixis ( EXEL ) Up 10.9% Since Last Earnings Report?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 6, 2024 (16:40) / "Zacks Commentary" (by Zacks Equity Research)
EXEL vs. REGN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis ( EXEL Quick QuoteEXEL - ) and Regeneron ( REGN Quick QuoteREGN - ) . But which of these two stocks offers value investors a better bang for their buck right now?
In Article Trend: Bullish
March 2, 2024 (10:06) / "Motley Fool" (by Sean Williams)
4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.
In Article Trend: Somewhat-Bullish
March 1, 2024 (14:15) / "Zacks Commentary" (by Zacks Equity Research)
ANI Pharmaceuticals, Inc. ( ANIP ) Hit a 52 Week High, Can the Run Continue?
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
Aurora Cannabis Inc. (ACB)
Cue Health Inc. (HLTH)
BioDelivery Sciences International, Inc. (BDSI)
Immuron Limited (IMRN)
Mesoblast Limited (MESO)
Antares Pharma, Inc. (ATRS)
Turning Point Therapeutics, Inc. (TPTX)
ACADIA Pharmaceuticals Inc. (ACAD)
Johnson & Johnson (JNJ)
Tactile Systems Technology, Inc. (TCMD)
This website uses cookies to ensure you get the best experience on our website